ArticleProceedings of the National Academy of Sciences of the United States of America2025
Therapeutic hypothermia reprograms nanocarrier protein corona via apolipoprotein C1 enrichment for precision cardiovascular therapy.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Asymmetric nanozymes improve cardiac purine catabolism and alleviate oxidative stress of myocardium to treat ischemic heart disease.Journal of nanobiotechnology · 2026Article
- Clinical Value of Serum APOC1, LMNA, and TPM4 in Predicting Fetal Cardiac Abnormalities in Elderly Parturients.International journal of women's health · 2026Article
- Thermally Induced Reassembly of Ginger Extracellular Vesicles for Oral Therapy of Intestinal Inflammation.Research (Washington, D.C.) · 2026Article
- Therapeutic hypothermia reprograms nanocarrier protein corona via apolipoprotein C1 enrichment for precision cardiovascular therapy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cardiovascular diseases (CVDs), the primary cause of global mortality, face persistent therapeutic challenges due to poor drug targeting and systemic side effects. While innovative nanotherapeutic approaches offer improved drug delivery through targeting and stimulus-responsive release mechanisms, clinical translation is limited by poor tissue specificity and manufacturing limitations. We present a universal therapeutic hypothermia (TH, i.e., 32 to 35 °C)-enhanced strategy that amplifies nanocarrier targeting across multiple CVD models. Both hard and soft nanocarriers showed 1.6- to 3-fold increased pathological tissue accumulation under TH versus normothermia, correlating with enhanced therapeutic efficacy in multiple murine models of CVDs, including heart failure, myocardial hypertrophy, ventricular fibrillation, ischemic stroke, atherosclerosis, and deep vein thrombosis. Mechanistically, TH induces temperature-dependent enrichment of apolipoproteins C1 (ApoC1) and C4 in the protein corona of nanoparticle surface, enabling receptor-mediated targeting through upregulated lipoprotein receptors in injured cardiovascular tissues. Notably, ApoC1-mediated targeting outperformed established cardiac-targeting peptides in directing nanoparticles to diseased hearts. The TH-driven approach and direct ApoC1 functionalization provide a straightforward, scalable, and cost-effective approach to enhance nanotherapy precision for CVD treatment, potentially addressing critical barriers in clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.